- Same Thing
- Side Effects
- What Is
- Drug Interactions
Are Nubeqa and Rubraca the Same Thing?
Nubeqa (darolutamide) and Rubraca (rucaparib tablets) are used to treat different types of cancer.
Nubeqa is indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.
Rubraca is indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Patients are selected for therapy based on an FDA-approved companion diagnostic for Rubraca.
Nubeqa and Rubraca belong to different drug classes. Nubeqa is an androgen receptor inhibitor and Rubraca is a poly (ADP-ribose) polymerase (PARP) inhibitor.
Side effects of Nubeqa and Rubraca that are similar include fatigue and rash.
Side effects of Nubeqa that are different from Rubraca include pain in extremities.
Side effects of Rubraca that are different from Nubeqa include nausea, vomiting, anemia, abdominal pain, changes in taste, constipation, decreased appetite, diarrhea, low levels of platelets in the blood (thrombocytopenia), shortness of breath, dizziness, low levels of white blood cells (neutropenia), fever, skin sensitivity to sunlight, and itching.
Nubeqa may interact with rifampicin, itraconazole, midazolam, and rosuvastatin.
Rubraca may interact with other drugs.
What Are Possible Side Effects of Nubeqa?
Common side effects of Nubeqa include:
- pain in extremities, and
What Are Possible Side Effects of Rubraca?
Common side effects of Rubraca include:
- fatigue (including weakness),
- abdominal pain,
- changes in taste,
- decreased appetite,
- low levels of platelets in the blood (thrombocytopenia),
- shortness of breath,
- low levels of while blood cells (neutropenia),
- skin sensitivity to sunlight, and
What Is Nubeqa?
Nubeqa (darolutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.
What Is Rubraca?
Rubraca (rucaparib tablets) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Patients are selected for therapy based on an FDA-approved companion diagnostic for Rubraca.
What Drugs Interact With Nubeqa?
Nubeqa may interact with rifampicin, itraconazole, midazolam, and rosuvastatin. Tell your doctor all medications and supplements you use.
How Should Nubeqa be Taken?
The dose of Nubeqa is 600 mg, (two 300 mg tablets) administered orally twice daily with food. Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.
Health Solutions From Our Sponsors
All drug information provided on RxList.com is sourced directly from drug monographs published by the U.S. Food and Drug Administration (FDA).
Any drug information published on RxList.com regarding general drug information, drug side effects, drug usage, dosage, and more are sourced from the original drug documentation found in its FDA drug monograph.
Drug information found in the drug comparisons published on RxList.com is primarily sourced from the FDA drug information. The drug comparison information found in this article does not contain any data from clinical trials with human participants or animals performed by any of the drug manufacturers comparing the drugs.
The drug comparisons information provided does not cover every potential use, warning, drug interaction, side effect, or adverse or allergic reaction. RxList.com assumes no responsibility for any healthcare administered to a person based on the information found on this site.
As drug information can and will change at any time, RxList.com makes every effort to update its drug information. Due to the time-sensitive nature of drug information, RxList.com makes no guarantees that the information provided is the most current.
Any missing drug warnings or information does not in any way guarantee the safety, effectiveness, or the lack of adverse effects of any drug. The drug information provided is intended for reference only and should not be used as a substitute for medical advice.
If you have specific questions regarding a drug’s safety, side effects, usage, warnings, etc., you should contact your doctor or pharmacist, or refer to the individual drug monograph details found on the FDA.gov or RxList.com websites for more information.
You may also report negative side effects of prescription drugs to the FDA by visiting the FDA MedWatch website or calling 1-800-FDA-1088.
Clovis Oncology. Rubraca Product Information.